Objective: MicroRNAs have emerged as a new class of non-coding genes involved in regulating cell proliferation, differentiation and viability. Recent studies have identified miR-210 as one of a set of hypoxia-regulated microRNAs and demonstrated a direct regulatory role of HIF-1 alpha for its transcription. Here, we assessed miR-210 expression in Japanese triplenegative breast cancers and determined its clinical significance. Methods: TaqMan MicroRNA assays for miR-210 expression were performed on 161 samples of Japanese breast cancer tissue (58 triple-negative breast cancer and 103 estrogen receptor positive/HER2 negative). Correlations between miR-210 expression and clinicopathological factors were analyzed. The effects of several variables on survival were tested by a Cox proportional hazards regression analysis. Results: miR-210 expression in triple-negative breast cancers was significantly higher than in estrogen receptor-positive/HER2-negative breast cancers (P , 0.001). Patients whose triplenegative breast cancers showed low miR-210 expression experienced significantly better disease-free and overall survival than those with high miR-210 expression (P ¼ 0.02 and P ¼ 0.05, respectively). Although the prognosis of patients with triple-negative breast cancers is poor, Cox univariate and multivariate analyses demonstrated that a higher expression of miR-210 was an independent factor indicating a worse prognosis than for patients with a low level of miR-210. Conclusions: The degree of miR-210 expression might be a clinically useful prognostic factor for decision-making regarding treatment in the adjuvant setting, especially in nodenegative triple-negative breast cancer patients.
INTRODUCTION
MicroRNAs (miRNAs) have emerged as a new class of noncoding genes involved in regulating cell proliferation, differentiation and viability (1) . miRNAs are single-strand small RNA molecules that are between 19 and 22 nucleotides in length. miRNAs primarily regulate gene expression through the inhibition of RNA translation by base pairing of their 'seed region', nucleotides 2 -8, to the 3 0 untranslated region of the target RNAs (2) . miRNA can also facilitate targeting of specific mRNAs for cleavage, resulting in the downregulation of target mRNAs (3) .
Hypoxia is a common feature of pathological conditions such as tissue ischemia and inflammation, as well as solid tumors (4) . Multiple hypoxic responses that impact tumorigenesis are mediated through the hypoxia-inducible factors (HIFs), composed of alpha (HIF-a) and beta (HIF-b; ARNT) subunits (4) . Under hypoxia, HIF-a subunits are stabilized and heterodimerize with HIF-b in the nucleus. This heterodimeric complex binds to hypoxia response elements (HREs) and modulates the expression of multiple target genes that are important for angiogenesis, cell survival and tumorigenesis. Two HIF-a proteins, HIF-1a and HIF-2a regulate the expression of overlapping and unique target genes (4) . In addition to the transcriptional activation of multiple genes, hypoxia is also involved in the regulation of miRNAs (5) .
Several studies have reported that miR-210 is a highly up-regulated miRNA in hypoxic cells and have demonstrated its importance for cell survival (6 -8) . miR-210 was shown to be HIF-1a dependent and to have a functional role during tumor initiation (7) . A recent study showed that HIF-1a could be a predominant and sufficient regulator of miR-210; however, in the presence of HIF-1a, HIF-2a could also mediate miR-210 expression (8) . In addition to being one of the predominant hypoxia-inducible miRNAs, the expression of miR-210 is reported to be up-regulated in many cancers including breast (9,10), non-small-cell lung (11), head and neck (12) and pancreatic cancers (13) , glioblastoma (14) , malignant melanoma (8, 15) and renal cell carcinoma (16) . Overexpression of miR-210 was shown to indicate a poor prognosis in breast cancer patients (9,10), head and neck (12) and pancreatic cancer patients (13) . miR-210 was also shown to be overexpressed at late stages of non-small-cell lung cancer (11) .
Emerging data demonstrate that stratification of tumors by gene expression profiles divides breast cancer into four common subtypes that are associated with different clinical outcomes (17) . Two of them are estrogen receptor (ER) positive (luminal and luminal/HER2þ) and two are ER negative (basal-like and HER2 positive) (17, 18) . Although the immunohistochemical staining profile can be a useful surrogate for gene expression analysis, the optimal immunohistochemical profile of the basal-like subtype remains unclear. However, the basal-like category is composed almost entirely of triplenegative breast cancers (TNBCs; tumors lacking ER, progesterone receptor (PgR) and HER2 expression) (18, 19) . A simplified method of classification, based on immunohistochemical assays for ER, PgR and HER2, is clinically useful, and clinicians are increasingly taking triple-negative status into account in clinical decision-making and therapeutic protocol design. Triple-negative and basal-like tumors account for about 10 -15% of all invasive breast cancers, and they usually have higher histological grades and more aggressive clinical behavior than hormone receptor-positive breast cancers (20, 21) .
In this study, we investigated the correlations between miR-210 expression, and clinicopathological parameters and prognosis in Japanese TNBC patients.
METHODS

PATIENTS
A total of 161 surgically resected breast carcinomas with tissues available were selected from the archive of the Department of Breast and Endocrine Surgery, Nagoya City University Hospital in Japan. Specimens were obtained from patients who underwent surgery between January 1996 and July 2007. Tissues were fixed in 10% buffered formalin and embedded in paraffin and/or placed in liquid nitrogen immediately after resection and stored at 2808C until RNA extraction. Informed consent was obtained before the surgery. The histological grade was estimated according to the Bloom and Richardson method proposed by Elston and Ellis (22) . Disease-free survival (DFS) was defined as the interval from the date of primary surgery to the earliest occurrence of one of the following: locoregional recurrence, distant metastasis or death from any cause. Overall survival (OS) was defined as the interval from the date of primary surgery to death from any cause. The median follow-up period was 5.4 years (range 3 -149 months). This protocol was approved by the Institutional Review Board of Nagoya City University Graduate School of Medical Sciences and conformed to the guidelines of the 1975 Declaration of Helsinki.
QUANTITATIVE REVERSE TRANSCRIPTION-PCR DETECTION
OF MIRNA AND MRNA Total RNA from homogeneous microscopically confirmed breast cancer tissue was isolated from 500 mg of each frozen specimen with TRIZOL reagent (Invitrogen Japan K.K., Tokyo, Japan) for RNA extraction according to the manufacturer's recommendations as described previously (21) . cDNA was reverse transcribed from total RNA samples using specific miRNA primers from the TaqMan MicroRNA Assays and reagents from the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). The resulting cDNA was amplified by PCR using TaqMan MicroRNA Assay primers with the TaqMan Universal PCR Master Mix and analyzed with a 7500 ABI Jpn J Clin Oncol 2012;42 (4) 257 PRISM Sequence Detector System according to the manufacturer's instructions (Applied Biosystems) as described previously (23) . The relative levels of miR-210 expression were calculated from the relevant signals by normalization with the signal for U6B miRNA expression. The assay names for miR-210 were has-mir-210 (Applied Biosystems).
IMMUNOHISTOCHEMICAL ANALYSIS
ERa and PgR protein expression status was confirmed by immunohistochemistry (IHC) as follows. One 4-mm section of each submitted paraffin block was stained first with hematoxylin and eosin to verify that an adequate number of invasive carcinoma cells were present and that the fixation quality was adequate for IHC analysis. Serial sections (4 mm) were prepared from selected blocks and float mounted on adhesive-coated glass slides, for staining with monoclonal mouse anti-human ERa antibody (1D5; DAKO, Glostrup, Denmark) at 1:100 dilution and monoclonal mouse anti-human PgR antibody (636; DAKO) as described previously (21) . The DAKO Envision system (DAKO EnVision-labeled polymer, peroxidase) was used for detection. Immunostaining for epidermal growth factor receptor (EGFR) was performed using the EGFRpharmDx assay detection system (prediluted; DAKO). After the entire slide was evaluated by light microscopy, expression of ERa and PgR was scored by proportion and intensity, according to Allred's procedure (24) . In brief, the proportion scores that represented the estimated proportion of tumor cells staining positive were as follows: 0 (none), 1 (,1/100), 2 (1/100, ,1/10), 3 (1/10, ,1/3), 4 (1/3, ,2/3) and 5 (2/3). Any brown nuclear staining in invasive breast epithelium counted toward the proportion score. The intensity scores, representing the average intensity of the positive cells, were as follows: 0 (none), 1 (weak), 2 (intermediate) and 3 (strong). The proportion and intensity scores were then added to obtain a total score, which could range from 0 to 8. Tumors with a score of 0 or 2 were considered to be negative and those with a score of 3 or greater were considered to be positive for ERa expression. HER2 immunostaining was evaluated using the same method as is employed by the HercepTest (DAKO). To determine the score for HER2 expression the membrane staining pattern was assessed and scored on a scale of 0 to 3þ. Tumors with scores of 0 and 1 were considered to be negative for HER2 overexpression. To determine the score for EGFR expression, the membrane staining pattern was assessed and scored on a scale of 0 to 3þ using the same method as for the HER2 scoring. Tumors with scores of 0 and 1 were considered to be negative and tumors with scores of 2 and 3 were considered to be positive for EGFR overexpression.
STATISTICAL ANALYSES
All molecular and immunohistochemical analyses were performed blinded to clinical data. Statistical calculations were performed with StatView-J 5.0 software (SAS Institute, Inc., Cary, NC, USA). The Mann -Whitney U-test was performed for the analyses of ERa protein and miR-210 expression. The relationships between ERa protein expression or miR-210 expression, and clinicopathological factors were assessed by x 2 and Fisher's exact probability tests. DFS and OS curves were generated by the Kaplan -Meier method and verified by the log-rank test. A Cox proportional hazards regression analysis was used for univariate and multivariate analyses of prognostic values. Differences were considered significant when a P value , 0.05 was obtained.
RESULTS
MIR-210 EXPRESSION AND ERa STATUS
We examined the correlation between miR-210 expression and ERa protein expression in 161 samples of Japanese breast cancer tissue (58 triple-negative TNBC, and 103 ER positive and HER2 negative), because miR-210 has been linked to the metastatic potential of TNBCs (10) . In order to simplify the analysis, we excluded HER2-positive breast cancer from this analysis. In order to examine the relationship between miR-210 expression and ERa expression levels, we divided the ERa-positive, HER2-negative breast cancers (n ¼ 103) into two subgroups: one group showed low ERa protein expression (Allred score: 3 -6; n ¼ 42) and another group showed high ERa protein expression (Allred score: 7 or 8; n ¼ 61; Table 1 ). Except for tumor grade, the characteristics of the analyzed breast cancers were similar with regard to patient age, tumor size and nodal status among these two groups of ERa-positive, HER2-negative breast cancers and TNBCs (Table 1) . TNBCs showed higher tumor grades than did the ERa-positive and HER2-negative breast cancers. As shown in Fig. 1 , the miR-210 expression in TNBCs (median relative miR-210 expression: 6.2; average relative miR-210 expression: 11.1 + 2.60) was significantly higher than that in both the high ERa expression tumors (median 1.39, average 2.48 + 0.43; Mann -Whitney U-test, P , 0.001) and the low ERa expression tumors (median 1.51, average 3.15 + 0.61; Mann -Whitney U-test, P , 0.001).
MIR-210 EXPRESSION AS A PROGNOSTIC MARKER IN BREAST CANCER
Next, we examined the relationship between the expression of miR-210 in tumor specimens and patient outcome in 58 TNBCs with long-term follow-up. miR-210 expression showed a significant inverse correlation with DFS when divided at the median miR-210 expression level (log-rank test; P ¼ 0.046). Then, TNBCs were divided into three groups according to miR-210 expression levels: low expression (relative miR-210 expression ,4; n ¼ 19), intermediate expression (4 relative miR-210 expression ,9; n ¼ 19)
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microRNA-210 in breast cancer and high expression (relative miR-210 expression 9; n ¼ 20; Table 2 ). The characteristics of patients and their tumors in each group were similar with regard to age, tumor size, nodal status, grade, EGFR protein expression and adjuvant chemotherapy ( Table 2 ). As shown in Fig. 2a (Table 3) . Next, we studied the relationship between the expression of miR-210 and patient outcome in 40 node-negative TNBCs. Interestingly, the 5-year DFS was 60% in patients with high miR-210 expression tumors (n ¼ 11), while no patient with low-miR-210 expression tumors (n ¼ 14) revealed recurrent disease ( Fig. 3a and b) . DFS and OS curves in intermediate miR-210 expression tumors (n ¼ 15) fall between the curves representing low-and high miR-210 expression tumors ( Fig. 3a and b) . (26) . miR-210 has been reported to be highly up-regulated miRNAs in hypoxic cells, and its transcription is regulated by both HIF-1a (7, 9, 27) and HIF-2a (8) . HIF-1a directly binds to an HRE on the proximal miR-210 promoter (7) . When the miR-210 core promoter is compared across species, this HRE is highly conserved, indicating the importance of hypoxia in regulating miR-210 expression across species (28) . Recently, two groups have reported that a high 260 microRNA-210 in breast cancer expression of miR-210 in breast cancer patients was associated with a poor prognosis (9,10). As breast cancers are classified into several subtypes and the biology and the clinical outcome are different among its subtypes (17, 18, 21) , we hypothesized that miR-210 expression would vary among them. In this study, we showed that miR-210 expression in TNBCs was significantly higher than that in ER-positive and HER2-negative tumors. Because TNBCs are heterogeneous, we classified the tumors according to their miR-210 expression levels. We found that TNBC patients with low expression of miR-210 had a better prognosis than did those with intermediate-and high miR-210 expression tumors despite the clinicopathological characteristics of the patients, such as tumor grade and the rate of adjuvant chemotherapy, being similar among the three groups. Our data thus supported the report presented by another group (10) . Notably, among 40 node-negative TNBCs, the 5-year DFS was 60% in patients whose tumors had high or intermediate miR-210 expression, while no patient with low miR-210 expression experienced recurrent disease. As we did not perform microdissection to obtain cancer cells, the proportion of the normal cell fraction, e.g. lymphoid cells and stromal cells, in TNBC samples might have influenced our results.
Several targets of miR-210 have been reported recently (7,8,29 -31) . According to these reports, one of the most important roles of miR-210 appears to be associated with 'mitochondrial dysfunction'. Chan et al. (29) have recently reported that miR-210 targeted the iron -sulfur cluster assembly protein (ISCU), and two other groups also supported this conclusion (30, 31) . By repressing ISCU1/2 during hypoxia, miR-210 decreases the activity of prototypical iron -sulfur proteins controlling mitochondrial metabolism (29) . Consequently, miR-210 represses mitochondrial respiration. Puisségur et al. (11) have also reported that subunit D of succinate dehydrogenase complex (SDHD) is a direct target of miR-210. SDHD is an enzyme of the tricarboxylic acid cycle and a functional member of the mitochondrial respiratory chain (complex II) (32) .
The regulation of these mitochondrial components by the miR-210 pathway has contrasting consequences for the regulation of cell death and survival under normoxic or hypoxic conditions (11, 31) . miR-210 overexpression in normoxia would create a mitochondrial dysfunction including a mismatch in electron transport that could lead to an increase in toxic reactive oxygen species (31) and increased apoptosis Jpn J Clin Oncol 2012;42(4) 261 (11, 31) . miR-210 thus appears to exert a maladaptive role in normoxia (11, 31) . In contrast, during hypoxia, the miR-210-dependent repression of the electron transport chain via ISCU1/2 and SDHD would be protective by participating in the homeostatic down-regulation of mitochondrial respiration (6, 11, 29, 31) . The reduced mitochondrial respiration could be responsible for the tumor cell growth advantage in a hypoxic microenvironment. One hypothesis suggests that a reduced mitochondrial function could conserve O 2 for alternative use (33) . When the distance travelled by O 2 to reach the outermost cell was defined as the diffusion limit, the limit is a function of the O 2 content within the blood vessels and the rate of consumption within the tumor cells as O 2 diffuses out from the vessels. Decreasing consumption is theoretically the most efficient way to extend this diffusion limit in vivo (33, 34) . The second hypothesis suggests that a reduced mitochondrial function could yield an increase in anabolic substrates (33) . Rapidly dividing tumor cells require large amounts of precursors for proteins, nucleic acids and lipids (35) . An increased glucose uptake by tumor cells and a decreased consumption of metabolites for energy in the mitochondria provide more substrates for lipid and nucleic acid synthesis (33) .
Tumors with high miR-210 expression might have a growth advantage via reduced mitochondrial respiration in a hypoxic microenvironment. Because TNBCs usually have aggressive clinical behavior, they could have some areas of hypoxic microenvironment inside their tumors, where miR-210 could be highly expressed. On the other hand, HR-positive tumors are usually of lower histological grade and less aggressive than TNBCs. We demonstrated that miR-210 expression in TNBCs was higher than in HR-positive tumors. We consider that our data support the hypothesis described above. However, Camps et al. (9) have reported no interaction between ER and miR-210 expression levels. They evaluated ER status by ELISA while ER expression was confirmed by IHC analysis in the present study. Therefore, the methodology for evaluation of ER status might be responsible for these different results.
In this study, patients with TNBCs that expressed low levels of miR-210 had a more favorable prognosis, although the prognosis of TNBCs is relatively poor. Thus, the degree of miR-210 expression might be a clinically useful prognostic factor for decision-making regarding treatment in the adjuvant setting, especially in node-negative TNBC patients. Although we used frozen samples for this study, miRNA assays could also have been performed using formalin-fixed paraffin-embedded samples because technology has been rapidly advancing in this field. Although the multifaceted roles of miR-210 have been gradually clarified under hypoxia and normoxia status, the biological functions of miR-210 that are involved in providing a growth advantage for TNBCs are not fully understood. Further research might help to reveal that miR-210 could be not only a prognostic factor, but also a therapeutic target in TNBCs.
Funding
This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, grant # 21591674.
